Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 4,765 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Branch II Clear all

Conditions: Ulcerative Colitis
Interventions: Berberine Chloride, Laboratory Biomarker Analysis, Placebo Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Breast Carcinoma
Interventions: Best Practice, Discussion, Interview - Stakeholder, Interview - Key Informant, Interview - Ancillary studies, Patient Navigation - C Components, Patient Navigation - B components, Patient Navigation - A components, Survey Administration, Survey Administration - Ancillary studies; Other · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Non-Hodgkin's Lymphoma
Interventions: Clofarabine; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Carcinoid Tumor
Interventions: Axitinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Tampa, Florida

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: afatinib, placebo; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 272
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more

Conditions: Thyroid Cancer
Interventions: Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more

Conditions: Metastatic Renal Cell Carcinoma
Interventions: AS1411; Drug
Lead sponsor: Antisoma Research; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Duarte, California • Sacramento, California • San Francisco, California + 4 more

Conditions: Prostate Cancer
Interventions: Etoposide, Cyclophosphamide; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: East Brunswick, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 3 more

Conditions: Diastolic Dysfunction, Hypertension
Interventions: Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years and older
Enrollment: 317 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions: sargramostim, oral salt and soda mouthwash; Biological · Other
Lead sponsor: Marilyn Dodd; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoma
Interventions: Irinotecan&Temsirolimus:Arm1, Level 1, Irinotecan&Temsirolimus:Arm 1, Level 2, Irinotecan&Temsirolimus:Arm 2, Level 1; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 10 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
Interventions: Cabo + Dostarlimab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy, no Evidence of Disease
Interventions: retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
Interventions: vorinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Rockledge, Pennsylvania

Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure; Procedure · Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia

Conditions: Renal Cell Carcinoma
Interventions: everolimus and bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, pyrazoloacridine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 22
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more

Conditions: Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Best Practice, Laboratory Procedure, Quality-of-Life Assessment, Questionnaire Administration, Regorafenib, Trifluridine and Tipiracil Hydrochloride; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory Multiple Myeloma
Interventions: pomalidomide, bortezomib, dexamethasone, laboratory biomarker analysis, gene expression analysis; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
Interventions: questionnaire administration, standard follow-up care, educational intervention; Other · Procedure
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 30 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Lung Cancer
Interventions: Sorafenib, Placebo; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 141
States / cities: Stanford, California • Aurora, Colorado • Boulder, Colorado + 103 more

Conditions: Pancreatic Cancer, Periampullary Adenocarcinoma
Interventions: capecitabine, vorinostat, Radiotherapy, Surgery to remove tumor; Drug · Radiation · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hormone Receptor Positive Breast Cancer
Interventions: Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more

Search by objective public record fields.

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma

A Study of Axitinib in Advanced Carcinoid Tumors

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

A Phase II Study of AS1411 in Renal Cell Carcinoma

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer